Risankizumab shows faster response in bio naïve than in bio‐experienced psoriatic patients-Reference-Cited by-同舟云学术

Risankizumab shows faster response in bio naïve than in bio‐experienced psoriatic patients

Published:2022-06-22 Issue:10 Volume:36 Page:
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:Acad Dermatol Venereol

Author:

Mastorino L.¹^ORCID,Castelli F.²,Stroppiana E.¹,Verrone A.¹,Ortoncelli M.¹,Susca S.¹,Boskovic S.¹,Passerini S.G.¹,Macagno N.¹^ORCID,Cariti C.¹,Licciardello M.²,Solaroli C.²,Pertusi G.³,Aragone M.G.⁴,Baggini G.⁴,Addese C.⁵,Leporati C.⁵,Peila R.⁵,Giura M.T.⁶,Rossotto G.⁶,Pella P.⁷,Mocci L.⁸,Merlo G.⁸,Tiberio R.⁹,Graziola F.⁹,Quaglino P.¹^ORCID,Dapavo P.¹,Ribero S.¹^ORCID

Affiliation:

1. Department of Medical Sciences, Section of Dermatology University of Turin Torino Italy

2. Section of Dermatology Koelliker Hospital Turin Italy

3. Outpatient Clinic, Section of Dermatology ASL VC Vercelli Italy

4. Outpatient Clinic, Section of Dermatology ASL AL Alessandria Italy

5. Outpatient Clinic, Section of Dermatology ASLTO4 Ivrea Italy

6. Surgery Department, Section of Dermatology Cardinal Massaia Hospital ASL AT Asti Italy

7. Oncology Department, Section of Dermatology Degli Infermi Hospital, ASL BI Biella Italy

8. Section of Dermatology AO AL Santi Antonio e Biagio e Cesare Arrigo Alessandria Italy

9. Dermatologic Clinic AOU Maggiore della Carità Hospital Novara Italy

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.18314

Reference10 articles.

1. Risankizumab shows high efficacy and Maintenance in improvement of response until week 52;Mastorino L;Dermatol Ther,2022

2. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

3. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial*

4. Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic

5. Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience—IL PSO (Italian Landscape Psoriasis);Dermatology Practical & Conceptual;2024-04-30

2. Long-Term Effectiveness of Brodalumab for the Treatment of Moderate-To-Severe Psoriasis: A Real-Life Multicenter Study of Up to 3 Years in a Real-Life Italian Cohort;Dermatology Practical & Conceptual;2024-04-30

3. Effectiveness of biological therapy in reducing psoriasis-related cardiovascular risk;Expert Opinion on Biological Therapy;2024-04

4. Immunotherapy in cutaneous melanoma and biologics in psoriatic disease: similarities and differences from a clinical multidisciplinary perspective;Expert Opinion on Biological Therapy;2024-03-03

5. Efficacy of Risankizumab in Patients with Suboptimal Response or Failure to Ustekinumab: A Multicenter Retrospective Study in Spain;Dermatologic Therapy;2024-01